The company has not filed an annual or quarterly report since its FY2021 10-K, filed Mar 9, 2022. Its latest SEC filing is a SC 13G/A from Feb 10, 2023.
10-K for FY2021, filed Mar 9, 2022
The sections below describe the company as of the FY2021 annual report.
Markets prescription medicines for people with chronic pain and related conditions, and an oral treatment for adults with acute migraine.
10-K for FY2021, filed Mar 9, 2022
$166.7M
10-K for FY2021, filed Mar 10, 2022
$166.7M ↗Yes. It kept 51 cents of every revenue dollar as net income in FY2021 and turned 24 cents into free cash flow.
10-K for FY2021, filed Mar 10, 2022
$37.1MView ↗
10-K for FY2021, filed Mar 10, 2022
$84.9MView ↗
10-K for FY2021, filed Mar 10, 2022
$40.6MView ↗
8-K, filed Mar 22, 2022
As described in the Introductory Note above, on March 21, 2022, Purchaser irrevocably accepted for payment all Shares of BDSI Common Stock…View ↗
Grew. Revenue grew 2.7x in 4 years, from $62M in FY2017 to $166.7M in FY2021, about 28% a year.
Broader treatment areas
The older report frames the business around chronic pain; the latest describes marketed treatments across chronic pain, opioid dependence, opioid-induced constipation and acute migraine.
10-K for FY2018, filed Mar 14, 2019 10-K for FY2021, filed Mar 9, 2022BioDelivery Sciences International, Inc., (NASDAQ: BDSI), is a rapidly growing commercial-stage specialty pharmaceutical company dedicated…View ↗
Competes with Purdue Pharma, Indivior, Midatech Pharma, LTS, ARx, and Aquestive Therapeutics
10-K for FY2021, filed Mar 9, 2022A number of products are competitors to BELBUCA, including BuTrans from Purdue Pharma L.P., or Purdue, a transdermal formulation of…View ↗
Loading...
